Clinical trials: AIDS Vaccines
HIV Infections, HIV Seronegativity
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
- Trial name
- NCT00000809
- Testing
- Aluminum hydroxide, QS-21, MN rsgp120/HIV-1
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections, HIV Seronegativity
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe.
- Trial name
- NCT00000879
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205)
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pneumococcal Infections
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a…
- Trial name
- NCT00962780
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), Blood draw
- Where
- 11 sites in Romania, South Africa
- Volunteers
- 303 people
- Sponsor
- Pfizer
HIV Infections, Hepatitis B
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in…
- Conditions
- HIV Infections, Hepatitis B, Measles, Pneumococcal Infections
- Trial name
- NCT00013871
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent)
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers…
- Trial name
- NCT00107042
- Testing
- Recombivax, Twinrix
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth
- Trial name
- HVTN316 (NCT06613789)
- Testing
- 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum)
- Where
- South Africa
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Acquired Immunodeficiency Syndrome, HIV Infections
Analysis of Immune Responses to HIV Vaccines
This study will evaluate a test designed to measure immune system responses to HIV and HIV vaccines.
- Trial name
- NCT00068978
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination
The purpose of this study is to look at the effects of the HIV vaccine Remune on viral load (level of HIV in the blood) and on the way the immune system responds to HIV.
- Trial name
- NCT00005758
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen
- Where
- 17 sites in United States
- Volunteers
- 472 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV Infection, Hiv
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini
This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini.
- Conditions
- HPV Infection, Hiv, HPV Vaccine
- Trial name
- NCT04982614
- Testing
- Gardasil ® 9
- Where
- 5 sites in Eswatini
- Volunteers
- 1,403 people
- Sponsor
- Columbia University
HIV Infections
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
To determine the safety and immunogenicity of gp160 (MicroGeneSys), rgp120/HIV-1MN (Genentech), and rgp120/HIV-1SF2 (BIOCINE) and their adjuvants in HIV-infected children 1 month to 18 years of age.
- Trial name
- NCT00000762
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
The purpose of this study is to see whether or not an HIV vaccination will help the body control the amount of HIV virus in blood (viral load) in patients who are not taking anti-HIV medicines.
- Trial name
- NCT00021762
- Testing
- HIV-1 Immunogen, Structured Treatment Interruption
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Despite risk reduction counseling, some individuals in HIV vaccine trials or vaccine preparedness studies may engage in risk behavior that results in HIV infection.
- Trial name
- NCT00029913
- Testing
- Observation
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 54 people
- Sponsor
- HIV Vaccine Trials Network
Human Papillomavirus Infection
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly…
- Trial name
- NCT06281119
- Testing
- Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
- Where
- 4 sites in Kenya, Mozambique and 1 more
- Volunteers
- 450 people
- Sponsor
- Serum Institute of India Pvt. Ltd.
Human Immunodeficiency Virus (HIV)
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are…
- Trial name
- QLAIV (NCT02474901)
- Testing
- Quadrivalent Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HPV - Anogenital Human Papilloma Virus Infection, HIV Infections
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Phase IV prospective study measuring the immunogenicity (neutralizing antibody titles against each HPV vaccine genotype) of the 9-valent vaccine against HPV (Gardasil9®Merck) in HIV-positive women aged 15-40 years with fully…
- Trial name
- Papillon (NCT03391921)
- Testing
- Vaccine
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
HIV Infections
The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV
The purpose of this study is to determine the number of newly formed CD4 cells in children who have taken anti-HIV drugs. The study will also evaluate the effectiveness of the new CD4 cells in producing an immune response to…
- Trial name
- NCT00004735
- Testing
- Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infection
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
Synthetic HIV Peptide Vaccines (Treatment Protocol) We are conducting a study to evaluate the safety of two peptide vaccines (given alone or in combination) in patients with early HIV infection.
- Trial name
- NCT00001386
- Testing
- PCLUS 3-18 MN, PCLUS 6.1 MN
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
To evaluate the safety and immunogenicity of SF-2 rgp120 vaccine in MF59 versus MN rgp120 vaccine in alum in volunteers who are seronegative for HIV-1.
- Trial name
- NCT00001031
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2
- Where
- 7 sites in United States
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo.
- Trial name
- NCT02564523
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.